These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19363331)

  • 1. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.
    Ménard A; Solas C; Mokthari S; Bregigeon S; Drogoul MP; Tamalet C; Lacarelle B; Martin IP
    AIDS; 2009 Apr; 23(7):869-71. PubMed ID: 19363331
    [No Abstract]   [Full Text] [Related]  

  • 2. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
    Do VT; Higginson RT; Fulco PP
    Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
    Vento S; Vallone A
    AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
    [No Abstract]   [Full Text] [Related]  

  • 5. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
    Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
    Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
    Calcagno A; Nozza S; Bonora S; Castagna A; Gonzalez de Requena D; D'Avolio A; Lazzarin A; Di Perri G
    J Antimicrob Chemother; 2011 Aug; 66(8):1932-4. PubMed ID: 21642649
    [No Abstract]   [Full Text] [Related]  

  • 8. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
    Nozza S; Galli L; Bigoloni A; Nicola G; Pogliaghi M; Cossarini F; Salpietro S; Galli A; Della Torre L; Tambussi G; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e113-5. PubMed ID: 21350358
    [No Abstract]   [Full Text] [Related]  

  • 9. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
    Nozza S; Galli L; Bigoloni A; Gianotti N; Spagnuolo V; Carbone A; Chiappetta S; Ripa M; Tambussi G; Lazzarin A; Castagna A
    New Microbiol; 2014 Apr; 37(2):145-51. PubMed ID: 24858641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
    Nakamura H; Miyazaki N; Hosoya N; Koga M; Odawara T; Kikuchi T; Koibuchi T; Kawana-Tachikawa A; Fujii T; Miura T; Iwamoto A
    J Infect Chemother; 2011 Feb; 17(1):105-10. PubMed ID: 20585968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
    Cohen CJ; Berger DS; Blick G; Grossman HA; Jayaweera DT; Shalit P; Thompson M; Peeters M; de Béthune MP; Voorspoels E; Mack R; Woodfall B
    AIDS; 2009 Jan; 23(3):423-6. PubMed ID: 19114852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir and etravirine are active against HIV type 1 group O.
    Briz V; Garrido C; Poveda E; Morello J; Barreiro P; de Mendoza C; Soriano V
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):225-7. PubMed ID: 19239363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
    Cattaneo D; Gervasoni C
    AIDS; 2011 Apr; 25(7):1012-3; author reply 1011-2. PubMed ID: 21412129
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
    Florence E; De Wit S; Castagna A; Ribera E; Hill A; Vanaken H; van Delft Y; Marks S
    Int J STD AIDS; 2010 Mar; 21(3):224-5. PubMed ID: 20071441
    [No Abstract]   [Full Text] [Related]  

  • 17. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
    Clumeck N; Cahn P; Molina JM; Mills A; Nijs S; Vingerhoets J; Witek J
    Int J STD AIDS; 2010 Nov; 21(11):738-40. PubMed ID: 21187353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine concentrations in CSF in HIV-infected patients.
    Tiraboschi JM; Niubo J; Vila A; Perez-Pujol S; Podzamczer D
    J Antimicrob Chemother; 2012 Jun; 67(6):1446-8. PubMed ID: 22357802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
    Thuret I; Chaix ML; Tamalet C; Reliquet V; Firtion G; Tricoire J; Rabaud C; Frange P; Aumaître H; Blanche S
    AIDS; 2009 Nov; 23(17):2364-6. PubMed ID: 19823069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.